Literature DB >> 15659760

Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein.

J J H Chu1, R Rajamanonmani2, J Li1, R Bhuvanakantham1, J Lescar2, M-L Ng1.   

Abstract

The envelope glycoprotein located at the outermost surface of the flavivirus particle mediates entry of virus into host cells. In this study, the involvement of domain III of West Nile virus (WNV-DIII) envelope protein in binding to host cell surface was investigated. WNV-DIII was first expressed as a recombinant protein and purified after a solubilization and refolding procedure. The refolded WNV-DIII protein displays a content of beta-sheets consistent with known homologous structures of other flavivirus envelope DIII, shown by using circular dichroism analysis. Purified recombinant WNV-DIII protein was able to inhibit WNV entry into Vero cells and C6/36 mosquito cells. Recombinant WNV-DIII only partially blocked the entry of dengue-2 (Den 2) virus into Vero cells. However, entry of Den 2 virus into C6/36 was blocked effectively by recombinant WNV-DIII. Murine polyclonal serum produced against recombinant WNV-DIII protein inhibited infection with WNV and to a much lesser extent with Den 2 virus, as demonstrated by plaque neutralization assays. Together these results provided strong evidence that immunoglobulin-like DIII of WNV envelope protein is responsible for binding to receptor on the surface of host cells. The data also suggest that similar attachment molecule(s) or receptor(s) were used by WNV and Den 2 virus for entry into C6/36 mosquito cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15659760     DOI: 10.1099/vir.0.80411-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  78 in total

1.  Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody.

Authors:  Bimmi Shrestha; S Kyle Austin; Kimberly A Dowd; Abhishek N Prasad; Soonjeon Youn; Theodore C Pierson; Daved H Fremont; Gregory D Ebel; Michael S Diamond
Journal:  Virology       Date:  2012-03-09       Impact factor: 3.616

2.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

Review 3.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

4.  Human Monoclonal Fab Antibodies Against West Nile Virus and its Neutralizing Activity Analyzed in Vitro and in Vivo.

Authors:  Tao Duan; Monique Ferguson; Lintian Yuan; Fangling Xu; Guangyu Li
Journal:  J Antivir Antiretrovir       Date:  2009-11-01

5.  Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Authors:  Orly Gershoni-Yahalom; Shimon Landes; Smadar Kleiman-Shoval; David Ben-Nathan; Michal Kam; Bat-El Lachmi; Yevgeny Khinich; Michael Simanov; Itzhak Samina; Anat Eitan; Irun R Cohen; Bracha Rager-Zisman; Angel Porgador
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 6.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Refolding, crystallization and preliminary X-ray structural studies of the West Nile virus envelope (E) protein domain III.

Authors:  Fang Yuan; Zhiyong Lou; Xiaofeng Li; Yu Wai Chen; John I Bell; Zihe Rao; George F Gao
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-04-01

8.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Effector functions of camelid heavy-chain antibodies in immunity to West Nile virus.

Authors:  L P Daley; M A Kutzler; B W Bennett; M C Smith; A L Glaser; J A Appleton
Journal:  Clin Vaccine Immunol       Date:  2009-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.